Supreme Court to Drug Makers: No More ‘Pay to Delay’

What's Hot


The Most Sinful City in the U.S. Is … (Hint: It’s Not Vegas)Family

How a Mexican Tariff Will Boost the Cost of 6 Common PurchasesFamily

This Free Software Brings Old Laptops Back to LifeMore

How to Protect Yourself From the ‘Can You Hear Me?’ Phone ScamFamily

Report: Walmart to Begin Selling CarsCars

Where to Sell Your Stuff for Top DollarAround The House

Is Your TV Tracking You? Here’s How to Tell — and Prevent ItAround The House

11 Staging Tips to Help You Get Top Dollar When Selling Your HomeAround The House

8 Tuition-Free U.S. CollegesCollege

4 Car Insurers That Might Raise Rates Even When the Accident Wasn’t Your FaultCars

21 Restaurants Offering Free Food Right NowSaving Money

20 Simple Hacks to Make Your Stuff Last LongerAround The House

Trump Scraps FHA Rate Cut — What Does It Mean for You?Borrow

How to Invest If Trump Kills the ‘Fiduciary Rule’Grow

12 Surprising Ways to Wreck Your Credit ScoreBorrow

10 Overlooked Expenses That Ruin Your BudgetFamily

A brand-name company that tries to pay its generic competition to go away can now be sued for violating antitrust laws.

Pharmaceutical companies pay generic drug makers millions of dollars a year to keep their cheaper products off of the market. It’s a relatively cheap way to keep prices high and maintain profits, as we’ve written before. The practice has been called “pay to delay.”

Now, because of a new U.S. Supreme Court decision, the practice could cost drug makers in ways they hadn’t expected. The justices ruled 5-3 that brand-name drug companies can be sued under antitrust laws if they make such agreements, the Los Angeles Times says.

The ruling will likely lead to lower prices, the newspaper says; the Federal Trade Commission has said these back-room deals cost consumers and health plans $3.5 billion a year.

But it’s not an outright win for the FTC, which argued that the deals were usually illegal.

Instead, these arrangements will be judged on a case-by-case basis, the Times says. The court said drug makers can be sued, but the facts of each case will determine whether the payoff was reasonable to settle a patent dispute or an attempt to block competition.

Drug makers already get a long time to dominate the market before their patents expire. Patents can last as long as 20 years, the Times writes, and can often be extended an additional 20 years by tweaking the formula or how the drug is administered. But generic makers can challenge the extended monopoly, and that’s when these “pay to delay” settlements come into play.

Stacy Johnson

It's not the usual blah, blah, blah

I know... every site you visit wants you to subscribe to their newsletter. But our news and advice is actually worth reading! For 25 years, I've been making people richer without making their eyes glaze over. You'll be glad you did. I guarantee it!

💰🗣📰

Read Next: 25 Ways to Spend Less on Food

Check Out Our Hottest Deals!

We're always adding new deals and coupons that'll save you big bucks. See the deals to the right and hundreds more in our Deals section.

Click here to explore 1,909 more deals!